Condition
Exercise Tolerance
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownAsymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPDNCT07497230 · 2025-05-02
COMPLETEDM4C Nutraceutical Intervention Human Health Effects PilotNCT06476236 · 2024-06-17
UNKNOWNIntermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.NCT05379608 · 2021-12-10
COMPLETEDThe Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart FailureNCT03190304 · 2017-06-14
COMPLETEDEffects of an Exercise Rehabilitation Programme With a Nasal Inspiratory Restriction Device in COPD PatientsNCT03936348 · 2016-01-15
COMPLETEDStudy of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular DiseaseNCT01418248 · 2011-08-01
COMPLETEDEffects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic IncompetenceNCT01016431 · 2009-11-01
UNKNOWNCommon interventions
Asymmetric High-Flow Nasal Cannula (A-HFNC)DEVICE1Conventional Pulmonary Rehabilitation ProgramOTHER1EnalaprilDRUG1Exercise training program with and without FBDEVICE1Intermittent hypoxic-hyperoxic trainingPROCEDURE1Intermittent hypoxic-hyperoxic training/controlPROCEDURE1M4CDIETARY_SUPPLEMENT1NeprilysinDRUG1Rate-adaptive pacemaker programmingOTHER1VVI at 40 bpmOTHER1
Leading sponsors
Trial status mix
COMPLETED5
UNKNOWN2
Phase mix
NA4
PHASE42
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.